References
- Coglianese , C. ( 2009 ). The transparency president? The Obama administration and open government . Governance , 22 , 529 – 544 .
- European Medicines Agency . ( 2010 ). The European Medicines Agency Road Map to 2015: The agency's contribution to science, medicines, health . London , United Kingdom : Author .
- Fischhoff , B. ( 1995 ). Risk perception and communication unplugged: Twenty years of progress . Risk Analysis , 15 , 137 – 145 .
- Fischhoff , B. ( 2009 ). Risk perception and communication . In R. Detels , R. Beaglehole , M. A. Lansang & M. Gulliford (Eds.), Oxford textbook of public health, fifth edition (pp. 940 – 952 ). Oxford , United Kingdom : Oxford University Press .
- Garattini , S. , & Bertele , V. ( 2010 ). Europe's opportunity to open up on drug regulation . British Medical Journal , 340 , 842 – 843 .
- Grassley , C. ( 2007 , July 26 ). Floor statement of U.S. Senator Chuck Grassley of Iowa, FDA legislation.
- Hamburg , M. A. , & Sharfstein , J. ( 2009 ). The FDA as a public health agency . New England Journal of Medicine , 360 , 2493 – 2495 .
- Lancet . ( 2010 ). European Medicines Agency—More transparency needed . Lancet , 375 , 1753 .
- U.S. Food, & Drug Administration's Amendments Act . ( 2007 ). Title IX: Section 921. Adverse drug reaction reports and postmarket safety . Washington , DC : U.S. Congress .
- U.S. Food, & Drug Administration . ( 2010 ). FDA Transparency Initiative: Draft proposals for public comment regarding disclosure policies of the U.S. Food and Drug Administration . Rockville , MD : Author .